In Nairobi's sprawling informal settlements, a quiet shift is reshaping HIV prevention. Patients who once received pre-exposure prophylaxis (PrEP) through Kenya's public insurance scheme are now paying out of pocket at private pharmacies, buying single pills for 200 to 300 Kenyan shillings each. The change follows a decision by the National Hospital Insurance Fund (NHIF) to stop reauthorizing PrEP for many beneficiaries, leaving thousands without coverage for a drug that, when taken consistently, reduces HIV acquisition risk by over 90%.

Insurance Denial Forces PrEP Users Out of Care

NHIF, the state-run insurer covering roughly 40% of Kenya's population, began restricting PrEP reauthorizations in early 2025. Patients who had been on PrEP for months were told their coverage would not be renewed unless they submitted fresh documentation—a process that many clinics found cumbersome and slow. By mid-2025, HIV prevention clinics in Nairobi reported that a growing share of their PrEP clients were being denied continued coverage.

The denial creates a stark gap between policy and pharmacy reality. A patient who previously paid a copay of roughly 500 KES per month for PrEP now faces private-sector prices of 6,000–9,000 KES for a 30-day supply. That is roughly 12 to 18 times the public copay. For a minimum-wage worker earning about 15,000 KES per month, the cost is prohibitive.

In response, some patients have turned to private chemists that sell single doses without a prescription. These outlets, common in low-income neighborhoods, allow patients to buy a few pills at a time—enough for a week or two—but at a per-pill price that makes consistent adherence difficult. The result is a fragmented, unreliable prevention regimen.

HIV prevention advocates argue that the NHIF policy effectively shifts the financial burden from the insurer to the patient, undermining years of progress in getting PrEP to those who need it most. As one clinician in Kibera put it, "We're moving from a prevention program to a crisis-management model."

The Prior Authorization Loop in Kenya's Public Scheme

NHIF's PrEP coverage operates on a prior authorization model: patients must be approved every three months to continue receiving the drug. The process requires a clinician to submit a form documenting the patient's HIV-negative status, risk assessment, and adherence history. In theory, this ensures that PrEP is prescribed appropriately. In practice, the loop creates bottlenecks.

Clinics report that NHIF reviewers often take weeks to process reauthorization forms, during which patients go without coverage. Some forms are rejected for minor errors—a missing date, an unclear signature—and must be resubmitted. The HIV prevention unit at Kenyatta National Hospital estimates that roughly 40% of reauthorization requests are denied on first submission.

Denied patients frequently abandon the process altogether. A 2025 study by the Kenya Medical Research Institute found that only about half of patients whose PrEP reauthorization was denied ever reattempted the procedure. The rest either stopped PrEP entirely or sought it through private channels. The study's lead author described the prior authorization loop as "a filter that removes the most vulnerable patients from the prevention cascade."

The administrative burden also falls on clinics. Staff must track reauthorization dates, prepare forms, and follow up with NHIF—time that could be spent on patient care. For small clinics in peri-urban areas, the workload is unsustainable. Some have stopped offering PrEP altogether, referring patients to larger facilities that may be far from home.

NHIF defends the policy as necessary for cost control and adherence monitoring. A spokesperson noted that the three-month review period allows the insurer to verify that patients remain HIV-negative and are taking the drug correctly. But critics counter that the system is designed more for auditing than for patient retention, and that it creates a perverse incentive: patients who miss a reauthorization window are effectively penalized.

Private Pharmacies Fill the Void at a Cost

As NHIF coverage shrinks, private pharmacies in Nairobi have stepped into the breach. Many outlets now stock tenofovir-emtricitabine (Truvada or its generics) and sell it over the counter without a prescription. This is technically legal in Kenya, where PrEP is classified as a prescription drug but enforcement of the prescription requirement is weak.

A single pill costs 200–300 KES, depending on the pharmacy and the brand. A full month's supply—30 pills—thus runs 6,000–9,000 KES, far beyond what most NHIF beneficiaries can afford. But the single-pill option allows patients to buy just enough for a high-risk weekend or a few days of anticipated exposure. This episodic use, while better than nothing, is far from the daily regimen that clinical trials have shown to be most effective.

Pharmacists in Eastlands and Kawangware report that demand for single PrEP pills has risen sharply since early 2025. One pharmacist, who asked not to be named due to regulatory concerns, said he sells roughly 50 single pills per week, mostly to young women who say they cannot get refills from their clinic. "They come in, ask for 'the HIV prevention medicine,' and buy two or three pills. They know the price. They don't ask questions," he said.

The private pharmacy route also bypasses the clinical monitoring that is integral to PrEP programs. Patients who buy over the counter do not receive regular HIV testing, renal function checks, or adherence counseling. This raises the risk of undetected seroconversion and of drug-resistant viral strains emerging if patients take PrEP intermittently while unknowingly HIV-positive.

Public health officials acknowledge the gap but have struggled to respond. The Pharmacy and Poisons Board has issued warnings against dispensing PrEP without a prescription, but enforcement is sporadic. Meanwhile, the Kenya Medical Supplies Authority has not increased its distribution of PrEP to private pharmacies, leaving the market to unregulated wholesalers.

Why Insurers Balk at a Cost-Effective Drug

From an actuarial perspective, PrEP is a paradox. The wholesale price of tenofovir-emtricitabine has fallen to under 50 USD per person per year—roughly 6,500 KES—making it one of the most cost-effective preventive interventions available. Yet insurers in Kenya, including NHIF, have been reluctant to cover it broadly.

The core issue is that NHIF operates under a capped budget that prioritizes treatment over prevention. The fund's formulary is heavily weighted toward antiretroviral therapy for people living with HIV, which is seen as a mandatory expense. PrEP, by contrast, is classified as optional. When the fund needs to cut costs, prevention is the first line item to be reduced.

Adherence data also works against PrEP. Studies show that many PrEP users discontinue the drug within six months, often because of side effects (nausea, headache) or because their perceived risk of HIV declines. Insurers argue that paying for a drug that many patients stop taking is wasteful. Actuaries model PrEP as a high-turnover, low-adherence product, and adjust coverage accordingly.

But critics note that the same logic does not apply to other chronic medications. Antihypertensives and diabetes drugs also have adherence rates below 50%, yet NHIF covers them without requiring reauthorization every three months. The difference, some argue, is stigma. PrEP is associated with HIV and with behaviors—sex work, multiple partners, injection drug use—that insurers may implicitly devalue.

A 2024 analysis by the African Institute for Health Policy found that NHIF's PrEP denial rate was three times higher among patients in low-income areas than among those in high-income areas, even after controlling for clinical factors. The authors concluded that the prior authorization process introduces subjective bias that systematically disadvantages the poor.

HIV Incidence Stalls as Prevention Access Fragments

The impact of the NHIF policy change is already visible in epidemiological data. New HIV infections in Kisumu county, a high-prevalence region, plateaued in 2025 after several years of steady decline. The plateau coincides with a drop in PrEP enrollment at public clinics: enrollment fell by roughly 18% in the six months after NHIF stopped reauthorizing PrEP.

Young women aged 15–24 account for about 60% of new HIV infections in the region, and they are also the group most affected by the coverage gaps. Many rely on NHIF through their parents' or partners' policies, and they are often the first to lose coverage when reauthorization is denied. Private pharmacy sales, while increasing, cannot compensate for the loss of clinic-based care.

Clinics in Kisumu report that patients who stop PrEP often return months later with a new HIV diagnosis. One nurse at a facility in Kisumu East said, "We see them come in for testing after a high-risk event, and they say they couldn't get their PrEP refilled. Then they test positive. It's heartbreaking because we know it could have been prevented."

The stall in HIV prevention is not limited to PrEP. The same NHIF budget constraints have also reduced funding for outreach, counseling, and condom distribution. But PrEP is the most visible casualty, because it is a medicalized intervention that requires insurance coverage. Without it, the prevention toolkit shrinks.

International donors, including PEPFAR and the Global Fund, have historically supported Kenya's PrEP program, but their contributions are declining as Kenya transitions to domestic financing. The NHIF policy change accelerates that transition in a way that many public health experts consider premature. A 2025 report from UNAIDS warned that Kenya's HIV prevention gains could be reversed if domestic funding does not keep pace.

The Human Cost: Stories from the Ground

Behind the statistics are individual stories of disrupted prevention. In Mathare, a 24-year-old woman who works as a hairdresser described her experience: she had been on PrEP for eight months through a public clinic, paying the standard copay. When her reauthorization was denied in March 2025, she tried to appeal but could not afford the time away from work to queue at the NHIF office. She now buys single pills from a pharmacy near her salon, spending roughly 800 KES per week—about a quarter of her weekly income. "I skip days to make it last," she said. "I know it's not as effective, but it's better than nothing."

In Kibera, a community health worker recounted the case of a young man who had been on PrEP for over a year. After his coverage lapsed, he stopped taking the drug entirely. Three months later, he tested HIV-positive. "He told me he thought he could manage his risk without PrEP, but he couldn't," the health worker said. "The system failed him."

These accounts echo findings from a qualitative study conducted by researchers at the University of Nairobi in mid-2025. The study interviewed 30 PrEP users who had lost NHIF coverage. Nearly all reported difficulty adhering to the private pharmacy regimen, and several described episodes of unprotected sex without PrEP protection because they could not afford the pills. The study's lead author noted that the psychological burden of worrying about HIV acquisition, combined with financial strain, created a cycle of anxiety and inconsistent use.

Trade-Offs and Counter-Arguments

Not everyone agrees that the NHIF policy is purely detrimental. Some health economists argue that the prior authorization requirement, while flawed, serves a legitimate purpose: it prevents inappropriate prescribing and ensures that PrEP is targeted to those at highest risk. Without such checks, they contend, the program could become financially unsustainable, with low-risk patients using resources that could go to higher-impact interventions.

There is also a concern that eliminating the reauthorization requirement could lead to overuse and a rise in drug resistance if patients take PrEP intermittently without monitoring. A 2024 modeling study from the University of Oxford suggested that even a small increase in resistance due to poor adherence could offset the benefits of expanded access. However, the same study acknowledged that the current system's high dropout rate already undermines effectiveness.

Another counter-argument is that private pharmacy sales, though imperfect, provide a safety net for patients who would otherwise have no access at all. In areas where clinics are far or understaffed, the ability to buy a few pills at a local pharmacy may be the only realistic option. Some public health officials privately concede that turning a blind eye to over-the-counter sales has prevented a complete collapse of PrEP access.

Yet these arguments do not address the fundamental inequity: wealthier patients can afford to maintain continuous coverage through private insurance or out-of-pocket payments, while poorer patients are left to piece together a fragmented regimen. The NHIF policy, intended to control costs, ends up shifting the burden to those least able to bear it.

What a Functional Prevention System Would Look Like

Fixing the PrEP coverage gap does not require new drugs or massive spending. It requires rethinking the administrative and financial architecture of prevention. The most straightforward reform is to eliminate the three-month prior authorization requirement for PrEP and instead use electronic medical records to monitor adherence and HIV status passively.

Kenya's health information system, though imperfect, already captures HIV test results and pharmacy dispensing data. A dashboard that alerts clinicians when a patient misses a refill or tests positive could replace the cumbersome paper-based reauthorization process. Such a system would reduce administrative burden and prevent coverage lapses.

Another reform is to risk-pool PrEP costs across public and private insurers. Currently, NHIF bears the full cost for its beneficiaries, while private insurers often exclude PrEP entirely. A national risk pool for prevention, funded by a small levy on all health insurance premiums, could spread the cost and reduce the incentive for any single insurer to deny coverage.

Community pharmacy dispensing under standing orders is another promising model. In South Africa, trained pharmacists can initiate and refill PrEP without a doctor's visit, increasing access while maintaining monitoring. Kenya's Pharmacy and Poisons Board has piloted a similar program, but it remains limited to a few counties. Scaling it could reduce the need for clinic visits and make PrEP more accessible.

Finally, the national formulary must list PrEP as an essential preventive medicine, not as an optional add-on. That would require NHIF to cover it without periodic review, similar to vaccines or family planning. The cost is modest—roughly 50 USD per person per year—and the benefit, in terms of HIV infections averted, is large. But the decision is ultimately political, not technical.

This article is for informational purposes only and does not constitute personalized medical or insurance advice. Readers should consult their healthcare provider for guidance on HIV prevention and coverage options.